Chimeric Therapeutics (ASX:CHM) — Material Events
ASX:CHM · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Chimeric Therapeutics Shows 82% Disease Stability in Early CHM CDH17 CAR-T TrialMedium
Chimeric Therapeutics reports positive Phase 1/2 data for CHM CDH17 CAR-T in GI cancers
1 June 2026
·Clinical Trial Update
·85
Chimeric Therapeutics Secures $8.4M to Advance Promising CAR-T and NK Cell TrialsMedium
Chimeric Therapeutics advances clinical trials, secures $8.4M funding, FDA grants orphan drug status
28 Jan 2026
·Quarterly Activities Report
·85
Chimeric Therapeutics Secures $8.4M to Propel CHM CDH17 CAR-T Trial ForwardHigh
Chimeric Therapeutics raises $8.4M to fully fund CHM CDH17 CAR-T trial through Phase 1 amid strategic reset
23 Dec 2025
·Capital Raising
·85
Chimeric Therapeutics Shows 75% Disease Control in Early CAR-T TrialMedium
Chimeric Therapeutics reports 75% disease control in CHM CDH17 Phase 1/2 trial with durable responses
13 Nov 2025
·Clinical Trial Update
·85
Chimeric Therapeutics Reports 60% Complete Response in AML Phase 1B TrialMedium
Chimeric Therapeutics reports 60% complete response in Phase 1B AML trial with CHM CORE-NK
27 Apr 2026
·Clinical Trial Update
·Unexpected
·85
Chimeric Therapeutics Secures FDA Orphan Drug Status for Gastric Cancer TherapyMedium
Chimeric Therapeutics awarded FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
8 Dec 2025
·Regulatory Announcement
·85
Chimeric Therapeutics Advances Trials Amid Cash Crunch and New PartnershipsMedium
Chimeric Therapeutics advances clinical trials, appoints new director, secures manufacturing partnership, faces cash runway under half a quarter
31 Oct 2025
·Quarterly Activities Report and Appendix 4C
·80
Chimeric Therapeutics Shows Tumour Shrinkage at Highest CAR-T Dose in Phase 1 TrialMedium
Chimeric Therapeutics reports promising interim Phase 1 data for CHM CDH17 CAR-T therapy with tumor shrinkage and stable disease
16 July 2026
·Clinical Trial Update
·75
Chimeric Therapeutics Clarifies Timing of Key AML Trial Data Amid ASX QueryMedium
Chimeric Therapeutics clarifies timing and materiality of ADVENT-AML trial data disclosures following ASX query
6 Nov 2025
·ASX Query Response
·75
Chimeric Therapeutics Advances $1.8M on FY26 R&D Tax IncentiveMedium
Chimeric Therapeutics secures $1.8M advance on FY26 R&D tax incentive
2 Mar 2026
·Funding Announcement
·70
Chimeric Therapeutics Engages Adviser for Strategic Review to Unlock Hidden ValueMedium
Chimeric Therapeutics appoints independent adviser for strategic review to maximize shareholder value
1 July 2026
·Strategic Review Announcement
·70
Chimeric Therapeutics Secures $4.5M Boost for Cancer Cell Therapy R&DMedium
Chimeric Therapeutics secures $4.5M R&D tax incentive refund
24 Nov 2025
·ASX Announcement
·65
No articles in this tier for the last 12 months.
Market Mentions
9
- appeared in market wrap coverage
These are market wrap articles where Chimeric Therapeutics (ASX:CHM) was mentioned. They reflect broader market coverage, not company-specific announcements.
Market Wrap - Week 40 (28 Sept -> 2 Oct) 2026
3 Oct 2026
Healthcare Wrap - Week 40 (28 Sept -> 2 Oct) 2026
3 Oct 2026
Healthcare Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Healthcare Wrap - Week 27 (29 June -> 3 July) 2026
4 July 2026
Healthcare Wrap - Week 23 (1 June -> 5 June) 2026
6 June 2026